

Roland E Schmieder

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/8309246/publications.pdf](https://exaly.com/author-pdf/8309246/publications.pdf)

Version: 2024-02-01

345
papers

46,225
citations

7169

78
h-index

1875

209
g-index

369
all docs

369
docs citations

369
times ranked

31328
citing authors

#	ARTICLE	IF	CITATIONS
1	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 10-25.	0.8	30
2	Renal denervation in patients with chronic kidney disease: current evidence and future perspectives. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 1089-1096.	0.8	9
3	Renal denervation: where do we stand and what is the relevance to the nephrologist?. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 638-644.	0.8	20
4	Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. <i>Journal of Human Hypertension</i> , 2022, 36, 629-639.	2.3	14
5	Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 years. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 304-310.	0.8	22
6	Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trial. <i>Journal of Hypertension</i> , 2022, 40, 221-228.	0.5	6
7	Diagnosis and treatment of arterial hypertension 2021. <i>Kidney International</i> , 2022, 101, 36-46.	4.7	41
8	The influence of aircraft noise exposure on the systemic and renal haemodynamics. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 116-124.	1.8	6
9	Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. <i>Cardiovascular Diabetology</i> , 2022, 21, 4.	7.0	4
10	Renale Denervation. <i>Der Internist</i> , 2022, 63, 330-340.	0.3	0
11	Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2022, 21, 12.	7.0	11
12	The authors reply. <i>Kidney International</i> , 2022, 101, 830-832.	4.7	0
13	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. <i>Circulation</i> , 2022, 145, 847-863.	3.9	28
14	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL). <i>Hypertension</i> , 2022, 79, 1506-1514.	4.8	10
15	Editorial comment: Renal denervation. <i>Hypertension Research</i> , 2022, 45, 241-243.	2.5	6
16	Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial. <i>Hypertension</i> , 2022, 79, 1506-1514.	4.8	10
17	3D-Visualization of Neurovascular Compression at the Ventrolateral Medulla in Patients with Arterial Hypertension. <i>Clinical Neuroradiology</i> , 2021, 31, 335-345.	2.0	7
18	Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 725-731.	3.5	17

#	ARTICLE	IF	CITATIONS
19	How to measure retinal microperfusion in patients with arterial hypertension. <i>Blood Pressure</i> , 2021, 30, 4-19.	1.5	4
20	Reference values of retinal microcirculation parameters derived from a population random sample. <i>Microvascular Research</i> , 2021, 134, 104117.	2.5	5
21	Novel approaches to management of hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 54-62.	2.0	5
22	Improved blood pressure control via a novel chronic disease management model of care in sub-Saharan Africa: Real-world program implementation results. <i>Journal of Clinical Hypertension</i> , 2021, 23, 785-792.	2.0	11
23	Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. <i>Journal of Hypertension</i> , 2021, 39, 1602-1610.	0.5	5
24	Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 1562-1570.	3.1	6
25	Identifying Isolated Systolic Hypertension From Upper-Arm Cuff Blood Pressure Compared With Invasive Measurements. <i>Hypertension</i> , 2021, 77, 632-639.	4.8	4
26	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. <i>Journal of Hypertension</i> , 2021, 39, 766-774.	0.5	9
27	Neurogenic substance P influences on action potential production in afferent neurons of the kidney?. <i>Pflugers Archiv European Journal of Physiology</i> , 2021, 473, 633-646.	2.6	2
28	Hypertrophic remodelling of retinal arterioles in patients with congestive heart failure. <i>ESC Heart Failure</i> , 2021, 8, 1892-1900.	3.1	1
29	Dependency of flow-mediated vasodilatation from basal nitric oxide activity. <i>Clinical Physiology and Functional Imaging</i> , 2021, 41, 310-316.	1.1	6
30	Response to: Cavagna et al The importance of considering cultural and environmental elements in an interventional model of care to fight hypertension in Africa. <i>Journal of Clinical Hypertension</i> , 2021, 23, 1271-1272.	2.0	1
31	Association of Noise Annoyance with Measured Renal Hemodynamic Changes. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 323-330.	2.0	5
32	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2909-2919.	5.2	63
33	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN) Tj ETQq1 1 0.784314 rgBT /Overlock 13.3 197		
34	European Society of Hypertension position paper on renal denervation 2021. <i>Journal of Hypertension</i> , 2021, 39, 1733-1741.	0.5	88
35	Kriterien der Deutschen Gesellschaft für Kardiologie "Herz- und Kreislaufforschung e.V. (DGK), der Deutschen Hochdruckliga e.V. DHLÄ®/Deutschen Gesellschaft für Hypertonie und Prävention und der Deutschen Gesellschaft für Nephrologie (DGfN) zur Zertifizierung von "Renale-Denervations-Zentren (RDZ)" Update. <i>Kardiologie</i> , 2021, 15, 463-470.	0.4	6
36	Neurovascular Compression in Arterial Hypertension: Correlation of Clinical Data to 3D-Visualizations of MRI-Findings. <i>Open Neuroimaging Journal</i> , 2021, 14, 16-27.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1028-1038.	5.2	27
38	Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. <i>American Heart Journal</i> , 2021, 239, 90-99.	3.0	16
39	Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. <i>ESC Heart Failure</i> , 2021, 8, 5327-5337.	3.1	14
40	Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. <i>Cardiovascular Diabetology</i> , 2021, 20, 178.	7.0	10
41	Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010075.	4.1	8
42	Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 108055.	2.4	5
43	Detection of Changes in Renal Blood Flow Using Arterial Spin Labeling MRI. <i>American Journal of Nephrology</i> , 2021, 52, 69-75.	2.9	3
44	Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. <i>Journal of Hypertension</i> , 2021, 39, 162-168.	0.5	29
45	Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. <i>Cardiovascular Diabetology</i> , 2021, 20, 219.	7.0	30
46	Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. <i>European Heart Journal</i> , 2020, 41, 231-238.	2.4	35
47	Lumen narrowing and increased wall to lumen ratio of retinal microcirculation are valuable biomarkers of hypertension-mediated cardiac damage. <i>Blood Pressure</i> , 2020, 29, 70-79.	1.5	6
48	Medication adherence in hypertension. <i>Journal of Hypertension</i> , 2020, 38, 579-587.	0.5	55
49	Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 364-371.	3.1	11
50	Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids. <i>Theranostics</i> , 2020, 10, 8665-8676.	9.9	18
51	Retinal arterial remodeling in patients with pheochromocytoma or paraganglioma and its reversibility following surgical treatment. <i>Journal of Hypertension</i> , 2020, 38, 1551-1558.	0.5	3
52	Metabolische Wirkungen und kardiovaskuläre Sicherheit einer oralen Dreifachtherapie des Typ-2-Diabetes: das Beispiel Metformin, Empagliflozin und Linagliptin. <i>Diabetologie Und Stoffwechsel</i> , 2020, 15, 317-326.	0.1	0
53	Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. <i>Journal of Hypertension</i> , 2020, 38, 2050-2058.	0.5	9
54	12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2922-2933.	3.4	47

#	ARTICLE	IF	CITATIONS
55	Renal Denervation in High-Risk Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2879-2888.	5.2	80
56	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 1444-1451.	13.3	351
57	Changes in Stroke Volume After Renal Denervation. <i>Hypertension</i> , 2020, 75, 707-713.	4.8	11
58	Aortic stiffness is not only associated with structural but also functional parameters of retinal microcirculation. <i>Microvascular Research</i> , 2020, 129, 103974.	2.5	8
59	Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 471-484.	3.4	73
60	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. <i>Clinical Research in Cardiology</i> , 2020, 109, 289-302.	3.5	28
61	Influence of Age on Upper Arm Cuff Blood Pressure Measurement. <i>Hypertension</i> , 2020, 75, 844-850.	4.8	27
62	Facing the Challenge of Lowering Blood Pressure and Cholesterol in the Same Patient: Report of a Symposium at the European Society of Hypertension. <i>Cardiology and Therapy</i> , 2020, 9, 19-34.	2.7	18
63	Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography. <i>Scientific Reports</i> , 2020, 10, 5255.	3.4	10
64	Confounding Factors in Renal Denervation Trials. <i>Hypertension</i> , 2020, 76, 1410-1417.	4.8	33
65	Relationship Between Ubiquitin-Specific Peptidase 18 and Hypertension in Polish Adult Male Subjects: A Cross-Sectional Pilot Study. <i>Medical Science Monitor</i> , 2020, 26, e921919.	1.1	2
66	Assessment of Retinal Arteriolar Morphology by SLDF. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2020, , 27-41.	0.1	0
67	Tissue sodium content in hypertension and related organ damage. <i>Journal of Hypertension</i> , 2020, 38, 2363-2368.	0.5	5
68	Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. <i>Hypertension</i> , 2019, 74, 244-249.	4.8	17
69	Renal Denervation for Treating Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1095-1105.	3.4	61
70	Copeptin Levels in Patients With Treatment-Resistant Hypertension Before and 6 Months After Renal Denervation. <i>American Journal of Hypertension</i> , 2019, 33, 182-189.	1.9	1
71	Effects of the nitric oxide synthase inhibitor rolopterin (VAS203) on renal function in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 900-907.	2.5	10
72	Europäische Hypertonieleitlinien 2018 – was ändert sich?. <i>Der Internist</i> , 2019, 60, 202-208.	0.3	2

#	ARTICLE	IF	CITATIONS
73	Renal Denervation Update From the International Sympathetic Nervous System Summit. Journal of the American College of Cardiology, 2019, 73, 3006-3017.	5.2	74
74	Tissue sodium content in patients with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2019, 33, 485-489.	2.4	24
75	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. Circulation, 2019, 139, 2542-2553.	3.9	97
76	Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPPLICITY Registry. European Heart Journal, 2019, 40, 3474-3482.	2.4	189
77	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. European Heart Journal, 2019, 40, 2032-2043.	2.4	47
78	How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. Cardiovascular Diabetology, 2019, 18, 44.	7.0	80
79	Patient preference for therapies in hypertension: a cross-sectional survey of German patients. Clinical Research in Cardiology, 2019, 108, 1331-1342.	3.5	47
80	Effects of renal denervation on blood pressure in hypertensive patients with end-stage renal disease: a single centre experience. Clinical and Experimental Nephrology, 2019, 23, 749-755.	1.7	14
81	New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. International Journal of Cardiology: Hypertension, 2019, 3, 100022.	2.3	0
82	Left Ventricular Structure in Patients With Mild-to-Moderate CKD—a Magnetic Resonance Imaging Study. Kidney International Reports, 2019, 4, 267-274.	0.9	7
83	Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study. Nephrology Dialysis Transplantation, 2018, 33, gfw360.	0.8	14
84	Renal denervation improves 24-hour central and peripheral blood pressures, arterial stiffness, and peripheral resistance. Journal of Clinical Hypertension, 2018, 20, 366-372.	2.0	18
85	Percutaneous Creation of a Central Iliac Arteriovenous Anastomosis for the Treatment of Arterial Hypertension. Current Hypertension Reports, 2018, 20, 18.	3.5	5
86	Retinal capillary and arteriolar changes in patients with chronic kidney disease. Microvascular Research, 2018, 118, 121-127.	2.5	19
87	Retinal vascular resistance in arterial hypertension. Blood Pressure, 2018, 27, 82-87.	1.5	13
88	Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension — WAVE IV. Journal of Hypertension, 2018, 36, 680-689.	0.5	40
89	Impact of renal denervation on tissue Na ⁺ content in treatment-resistant hypertension. Clinical Research in Cardiology, 2018, 107, 42-48.	3.5	17
90	A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. American Heart Journal, 2018, 195, 115-129.	3.0	64

#	ARTICLE	IF	CITATIONS
91	Central arteriovenous anastomosis to treat resistant hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 8-15.	2.0	10
92	MASKed-unconTrolled hypERTension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. <i>BMJ Open</i> , 2018, 8, e021038.	2.1	33
93	Secretary Capacity of Pancreatic Beta-Cells Is Enhanced 6 Months After Renal Denervation in Hypertensive Patients. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3372-3374.	5.2	5
94	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>Journal of Hypertension</i> , 2018, 36, 1953-2041.	0.5	2,129
95	4325How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus?. <i>European Heart Journal</i> , 2018, 39, .	2.4	0
96	Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease. <i>Hypertension</i> , 2018, 72, 929-936.	4.8	29
97	Early vascular parameters in the micro- and macrocirculation in type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2018, 17, 128.	7.0	16
98	European Society of Hypertension position paper on renal denervation 2018. <i>Journal of Hypertension</i> , 2018, 36, 2042-2048.	0.5	39
99	Application of a central iliac arteriovenous coupler device in severe treatment-resistant hypertension. <i>Journal of Hypertension</i> , 2018, 36, 2471-2477.	0.5	1
100	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet, The</i> , 2018, 391, 2346-2355.	13.3	597
101	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. <i>Lancet, The</i> , 2018, 391, 2335-2345.	13.3	526
102	Assessment of Target Organ Damage. , 2018, , 189-199.		0
103	SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. <i>Cardiovascular Diabetology</i> , 2018, 17, 5.	7.0	147
104	Individualised treatment targets in patients with type-2 diabetes and hypertension. <i>Cardiovascular Diabetology</i> , 2018, 17, 18.	7.0	19
105	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 3021-3104.	2.4	6,826
106	Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120â€“140) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 trials. <i>European Heart Journal</i> , 2018, 39, 3105-3114.	2.4	92
107	Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.9	13
108	Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1867-1876.	0.6	157

#	ARTICLE	IF	CITATIONS
109	Low doseâ€oplere none treatment decreases aortic stiffness in patients with resistant hypertension. <i>Journal of Clinical Hypertension</i> , 2017, 19, 669-676.	2.0	24
110	A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. <i>Cardiovascular Diabetology</i> , 2017, 16, 26.	7.0	115
111	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>Lancet, The</i> , 2017, 389, 2226-2237.	13.3	263
112	Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 945-960.	1.2	59
113	Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension. <i>Hypertension</i> , 2017, 70, 1099-1105.	4.8	44
114	Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients. <i>Hypertension</i> , 2017, 70, 938-948.	4.8	31
115	Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 136, 1167-1169.	3.9	119
116	Accuracy of Cuff-Measured Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 572-586.	5.2	186
117	Expertise: No Longer a Sine Qua Non for Guideline Authors?. <i>Hypertension</i> , 2017, 70, 235-237.	4.8	4
118	Expertise. <i>Journal of Hypertension</i> , 2017, 35, 1564-1566.	0.5	12
119	Hypertonie und DyslipidÃmie. <i>Gastroenterologe</i> , 2017, 12, 294-299.	0.1	1
120	Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis. <i>Free Radical Research</i> , 2017, 51, 14-23.	3.3	9
121	Increased Aldosterone Release During Head-Up Tilt in Early Primary Hypertension. <i>American Journal of Hypertension</i> , 2017, 30, 484-489.	1.9	2
122	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. <i>Lancet, The</i> , 2017, 390, 2160-2170.	13.3	597
123	Retinal capillary rarefaction in patients with untreated mild-moderate hypertension. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 300.	1.7	33
124	Early Signs of EndÃrgan Damage in Retinal Arterioles in Patients with Type 2 Diabetes Compared to Hypertensive Patients. <i>Microcirculation</i> , 2016, 23, 447-455.	1.8	11
125	The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes. <i>Medicine (United States)</i> , 2016, 95, e3122.	1.1	8
126	Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT. <i>Journal of Hypertension</i> , 2016, 34, 393-396.	0.5	26

#	ARTICLE	IF	CITATIONS
127	Renal denervation reduces office and ambulatory heart rate in patients with uncontrolled hypertension. <i>Journal of Hypertension</i> , 2016, 34, 2480-2486.	0.5	19
128	Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.9	22
129	The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence. <i>Journal of Hypertension</i> , 2016, 34, 2475-2479.	0.5	8
130	Why in 2016 are patients with hypertension not 100% controlled? A call to action. <i>Journal of Hypertension</i> , 2016, 34, 1480-1488.	0.5	52
131	Non-invasive Renal Denervation: Update on External Ultrasound Approaches. <i>Current Hypertension Reports</i> , 2016, 18, 48.	3.5	7
132	Reproducibility of Kidney Perfusion Measurements With Arterial Spin Labeling at 1.5 Tesla MRI Combined With Semiautomatic Segmentation for Differential Cortical and Medullary Assessment. <i>Medicine (United States)</i> , 2016, 95, e3083.	1.1	19
133	Renal denervation in hypertensive patients not on blood pressure lowering drugs. <i>Clinical Research in Cardiology</i> , 2016, 105, 755-762.	3.5	21
134	Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial. <i>Diabetologia</i> , 2016, 59, 2579-2587.	6.7	19
135	Cocoa Flavanol Cardiovascular Effects Beyond Blood Pressure Reduction. <i>Journal of Clinical Hypertension</i> , 2016, 18, 352-358.	2.0	26
136	Two-Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Non-Interventional Prospective Study. <i>Journal of Clinical Hypertension</i> , 2016, 18, 647-654.	2.0	2
137	Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry. <i>Journal of Clinical Hypertension</i> , 2016, 18, 1045-1053.	2.0	2
138	Scientific Data and Transparency of Conflict of Interest Are Important, Not Biased Editorial Without Facts. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2263.	3.4	8
139	Improvement in Retinal Capillary Rarefaction After Valsartan Treatment in Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2016, 18, 1112-1118.	2.0	19
140	Diabetes und Hypertonie. <i>Diabetologe</i> , 2016, 12, 312-318.	0.2	0
141	Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 56.	1.7	22
142	Externally Delivered Focused Ultrasound for Renal Denervation. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1292-1299.	3.4	29
143	Adherence to Antihypertensive Medication in Treatment-Resistant Hypertension Undergoing Renal Denervation. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.9	54
144	Mid-Term Vascular Safety of Renal Denervation Assessed by Follow-up MR Imaging. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 426-432.	1.9	11

#	ARTICLE	IF	CITATIONS
145	Retinal Capillary Rarefaction in Patients with Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2016, 11, e0162608.	2.6	22
146	Will SPRINT change my practice? SPRINT: a randomised trial of intensive versus standard blood-pressure control. <i>EuroIntervention</i> , 2016, 12, 809-812.	3.3	2
147	Alternative Methods for Renal Denervation. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2016, , 321-337.	0.1	0
148	Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensinâ€Converting Enzyme Inhibitors: The Prospective <scp>EARLY</scp> Registry. <i>Journal of Clinical Hypertension</i> , 2015, 17, 947-953.	2.0	9
149	Effect of aliskiren on vascular remodelling in small retinal circulation. <i>Journal of Hypertension</i> , 2015, 33, 2491-2499.	0.5	13
150	The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry. <i>Trials</i> , 2015, 16, 581.	1.7	5
151	Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. <i>Journal of Hypertension</i> , 2015, 33, 1261-1266.	0.5	103
152	New developments in the pathogenesis of obesity-induced hypertension. <i>Journal of Hypertension</i> , 2015, 33, 1499-1508.	0.5	68
153	Managing Treatment-Resistant Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 11-13.	2.3	2
154	Retinal Circulation in Arterial Disease. , 2015, , 397-414.		2
155	Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6Âmonths results of the DIALOGUE registry. <i>BMC Endocrine Disorders</i> , 2015, 15, 23.	2.3	11
156	Olmesartan Improves Pulse Wave Velocity and Lowers Central Systolic Blood Pressure and Ambulatory Blood Pressure in Patients With Metabolic Syndrome. <i>Journal of Clinical Hypertension</i> , 2015, 17, 98-104.	2.0	8
157	Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. <i>Lancet, The</i> , 2015, 385, 1634-1641.	13.3	155
158	Circadian rhythm and day to day variability of serum potassium concentration: a pilot study. <i>Journal of Nephrology</i> , 2015, 28, 165-172.	2.1	11
159	Wilder's principle: pre-treatment value determines post-treatment response. <i>European Heart Journal</i> , 2015, 36, 576-579.	2.4	55
160	New Approaches in the Treatment of Hypertension. <i>Circulation Research</i> , 2015, 116, 1074-1095.	5.8	233
161	First Report of the Global SYMPLICITY Registry on the Effect of Renal Artery Denervation in Patients With Uncontrolled Hypertension. <i>Hypertension</i> , 2015, 65, 766-774.	4.8	172
162	Damage of Retinal Arterioles in Hypertension. , 2015, , 127-142.		0

#	ARTICLE	IF	CITATIONS
163	Renal Denervation for Resistant Hypertension: Past, Present, and Future. <i>Current Hypertension Reports</i> , 2015, 17, 65.	3.5	7
164	Retinal microperfusion after renal denervation in treatment-resistant hypertensive patients. <i>Clinical Research in Cardiology</i> , 2015, 104, 782-789.	3.5	4
165	Kardiale Auswirkungen einer Hypertonie. <i>Der Internist</i> , 2015, 56, 583-585.	0.3	0
166	Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension. <i>Clinical Research in Cardiology</i> , 2015, 104, 672-678.	3.5	42
167	Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin. <i>Clinical Research in Cardiology</i> , 2015, 104, 621-631.	3.5	15
168	Aldosterone Antagonists and Renal Denervation. <i>Hypertension</i> , 2015, 65, 280-282.	4.8	9
169	Reduced Effect of Percutaneous Renal Denervation on Blood Pressure in Patients With Isolated Systolic Hypertension. <i>Hypertension</i> , 2015, 65, 193-199.	4.8	109
170	The impact of age on the benefits and risks of aliskiren treatment: analyses of the 3A registry. <i>Journal of Human Hypertension</i> , 2015, 29, 316-323.	2.3	0
171	Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension. <i>EuroIntervention</i> , 2015, 11, 110-116.	3.3	45
172	Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy. <i>American Journal of Nephrology</i> , 2014, 40, 572-581.	2.9	33
173	Effects of folic acid on renal endothelial function in patients with diabetic nephropathy: results from a randomized trial. <i>Clinical Science</i> , 2014, 127, 499-505.	4.3	15
174	Urinary Albumin Excretion From Spot Urine Samples Predict All-Cause and Stroke Mortality in Africans. <i>American Journal of Hypertension</i> , 2014, 27, 811-818.	1.9	11
175	2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. <i>Blood Pressure</i> , 2014, 23, 3-16.	1.5	565
176	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline. <i>Journal of Hypertension</i> , 2014, 32, 1741-1750.	0.5	39
177	First experience in analysing pulsatile retinal capillary flow and arteriolar structural parameters measured noninvasively in hypertensive patients. <i>Journal of Hypertension</i> , 2014, 32, 2246-2252.	0.5	11
178	Disproportional Decrease in Office Blood Pressure Compared With 24-Hour Ambulatory Blood Pressure With Antihypertensive Treatment. <i>Hypertension</i> , 2014, 64, 1067-1072.	4.8	37
179	Improvement of albuminuria after renal denervation. <i>International Journal of Cardiology</i> , 2014, 173, 311-315.	1.6	69
180	Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2014, 13, 19.	7.0	56

#	ARTICLE	IF	CITATIONS
181	A guide for easy- and difficult-to-treat hypertension. <i>International Journal of Cardiology</i> , 2014, 172, 17-22.	1.6	19
182	Renal denervationâ€™implications for chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2014, 10, 305-313.	9.7	26
183	How should data from SYMPLICITY HTN-3 be interpreted?. <i>Nature Reviews Cardiology</i> , 2014, 11, 375-376.	13.9	18
184	1-Year outcomes of hypertension management in 13,000 outpatients under practice conditions: Prospective 3A registry. <i>International Journal of Cardiology</i> , 2014, 176, 589-594.	1.6	2
185	Diagnosis and treatment of resistant hypertension. <i>Blood Pressure</i> , 2014, 23, 193-199.	1.5	3
186	Invasive Treatment of Resistant Hypertension: Present and Future. <i>Current Hypertension Reports</i> , 2014, 16, 488.	3.5	7
187	Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. <i>Diabetologia</i> , 2014, 57, 2019-2029.	6.7	40
188	Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. <i>European Heart Journal</i> , 2014, 35, 1752-1759.	2.4	227
189	Clinical Impact of Patient Adherence to a Fixed-Dose Combination of Olmesartan, Amlodipine and Hydrochlorothiazide. <i>Clinical Drug Investigation</i> , 2014, 34, 403-411.	2.3	18
190	Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 558-565.	3.8	20
191	Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk. <i>Journal of Hypertension</i> , 2014, 32, 1334-1341.	0.5	14
192	Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient. <i>Journal of Hypertension</i> , 2014, 32, 1888-1897.	0.5	65
193	Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes. <i>Journal of Hypertension</i> , 2014, 32, 2267-2276.	0.5	5
194	What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. <i>EuroIntervention</i> , 2014, 9, 1027-1035.	3.3	46
195	EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy â€™ rationale and design of the EARLY hypertension registry. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 46.	1.7	7
196	Does Renal Artery Supply Indicate Treatment Success of Renal Denervation?. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 987-991.	1.9	7
197	25-Hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment. <i>Clinical Research in Cardiology</i> , 2013, 102, 299-304.	3.5	14
198	GuÃa de prÃctica clÃnica de la ESH/ESC para el manejo de la hipertensiÃn arterial (2013). <i>Hipertension Y Riesgo Vascular</i> , 2013, 30, 4-91.	0.7	10

#	ARTICLE	IF	CITATIONS
199	International Expert Consensus Statement. Journal of the American College of Cardiology, 2013, 62, 2031-2045.	5.2	124
200	Renal Denervation in Moderate Treatment-Resistant Hypertension. Journal of the American College of Cardiology, 2013, 62, 1880-1886.	5.2	93
201	Catheter-Based Renal Nerve Ablation and Centrally Generated Sympathetic Activity in Difficult-to-Control Hypertensive Patients: Prospective Case Series. Hypertension, 2013, 61, e17.	4.8	7
202	²³ Na Magnetic Resonance Imaging-Determined Tissue Sodium in Healthy Subjects and Hypertensive Patients. Hypertension, 2013, 61, 635-640.	4.8	332
203	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). Revista Espanola De Cardiologia, 2013, 66, 880.e1-880.e64.	1.3	24
204	Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension. British Journal of Clinical Pharmacology, 2013, 75, 129-135.	2.5	25
205	Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. International Journal of Cardiology, 2013, 168, 2214-2220.	1.6	122
206	2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2013, 22, 193-278.	1.5	355
207	Central Pulse Pressure Is an Independent Determinant of Vascular Remodeling in the Retinal Circulation. Hypertension, 2013, 61, 1340-1345.	4.8	68
208	Poor Glycemic Control Is Related to Increased Nitric Oxide Activity Within the Renal Circulation of Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 4071-4075.	8.9	13
209	Blood pressure and retinal small arteries. Journal of Hypertension, 2013, 31, 1946-1947.	0.5	0
210	2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension, 2013, 31, 1281-1357.	0.5	4,251
211	Optimizing blood pressure control in hypertension: The need to use ABPM. Blood Pressure, 2013, 22, 65-72.	1.5	7
212	Vascular and Renal Hemodynamic Changes after Renal Denervation. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1195-1201.	4.5	51
213	Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension. Circulation, 2013, 128, 132-140.	3.9	240
214	2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Journal of Hypertension, 2013, 31, 1925-1938.	0.5	789
215	Local application of tropicamide 0.5% reduces retinal capillary blood flow. Blood Pressure, 2013, 22, 371-376.	1.5	27
216	Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring. Journal of Human Hypertension, 2013, 27, 715-720.	2.3	18

#	ARTICLE	IF	CITATIONS
217	Review of direct renin inhibition by aliskiren. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2013, 14, 193-196.	1.7	19
218	Haemoglobin and vascular function in the human retinal vascular bed. Journal of Hypertension, 2013, 31, 775-781.	0.5	4
219	Clinical situations associated with difficult-to-control hypertension. Journal of Hypertension, 2013, 31, S3-S8.	0.5	19
220	Catheter-based Renal Sympathetic Denervation â€“ Long-term Symplicityâ„¢ Renal Denervation Clinical Evidence, New Data and Future Perspectives. Interventional Cardiology Review, 2013, 8, 118.	1.6	6
221	Rationale and design of a large registry on renal denervation: the Global SYMPPLICITY registry. EuroIntervention, 2013, 9, 484-492.	3.3	56
222	Updated ESH position paper on interventional therapy of resistant hypertension. EuroIntervention, 2013, 9, R58-R66.	3.3	60
223	Ruling out secondary causes of hypertension. EuroIntervention, 2013, 9, R21-R28.	3.3	6
224	Tonic Postganglionic Sympathetic Inhibition Induced by Afferent Renal Nerves?. Hypertension, 2012, 59, 467-476.	4.8	38
225	Chronobiologie des Blutdrucks und Chronopharmakotherapie der arteriellen Hypertonie. Deutsche Medizinische Wochenschrift, 2012, 137, 317-321.	0.2	3
226	Diagnostik, Bedeutung, PrÃvention und Therapie einer Mikroalbuminurie. Deutsche Medizinische Wochenschrift, 2012, 137, 1409-1420.	0.2	1
227	Impaired Increase of Retinal Capillary Blood Flow to Flicker Light Exposure in Arterial Hypertension. Hypertension, 2012, 60, 871-876.	4.8	24
228	Reversibility of the Effects of Aliskiren in the Renal Versus Systemic Circulation. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 258-264.	4.5	11
229	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension. Journal of Hypertension, 2012, 30, 1047-1055.	0.5	134
230	Hypertension and atrial fibrillation. Journal of Hypertension, 2012, 30, 239-252.	0.5	177
231	Comment on ESH position paper. Journal of Hypertension, 2012, 30, 2443.	0.5	4
232	ESH Position Paper. Journal of Hypertension, 2012, 30, 837-841.	0.5	227
233	Wall-to-lumen ratio of retinal arterioles. Journal of Hypertension, 2012, 30, 1108-1110.	0.5	7
234	²³ Na Magnetic Resonance Imaging of Tissue Sodium. Hypertension, 2012, 59, 167-172.	4.8	223

#	ARTICLE	IF	CITATIONS
235	Current status of renal denervation in resistant hypertension. Journal of the American Society of Hypertension, 2012, 6, 414-416.	2.2	2
236	Hypertensive Krise. MMW Fortschritte Der Medizin, 2012, 154, 56-57.	0.0	0
237	Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension. Circulation, 2012, 126, 2976-2982.	3.9	420
238	Salt and Hypertension: Is Salt Dietary Reduction Worth the Effort?. American Journal of Medicine, 2012, 125, 433-439.	1.4	154
239	Influence of blood flow on arteriolar wall-to-lumen ratio in the human retinal circulation in vivo. Microvascular Research, 2012, 83, 111-117.	2.5	20
240	Rosuvastatin improves pulse wave reflection by restoring endothelial function. Microvascular Research, 2012, 84, 60-64.	2.5	14
241	Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice – study rationale and protocol of DIALOGUE. Cardiovascular Diabetology, 2012, 11, 148.	7.0	5
242	Renal Denervation in a Hypertensive Patient With End-stage Renal Disease and Small Arteries: A Direction for Future Research. Journal of Clinical Hypertension, 2012, 14, 799-801.	2.0	35
243	Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension. Hypertension, 2012, 60, 419-424.	4.8	289
244	Barriers to cardiovascular risk prevention and management in Germany – an analysis of the EURIKA study. Vascular Health and Risk Management, 2012, 8, 177.	2.4	13
245	The Optic Fundus and Retinal Circulation: New Technology for an Old Examination. , 2012, , 157-168.		0
246	Validation of a therapeutic scheme for the treatment of resistant hypertension. Journal of the American Society of Hypertension, 2011, 5, 498-504.	2.2	21
247	New software analyses increase the reliability of measurements of retinal arterioles morphology by scanning laser Doppler flowmetry in humans. Journal of Hypertension, 2011, 29, 777-782.	0.5	59
248	Basal nitric oxide activity is an independent determinant of arteriolar structure in the human retinal circulation. Journal of Hypertension, 2011, 29, 123-129.	0.5	14
249	Physician attitudes to blood pressure control. Journal of Hypertension, 2011, 29, 1633-1640.	0.5	37
250	Cerebral Microangiopathy in Treatment-resistant Hypertension. Journal of Clinical Hypertension, 2011, 13, 582-587.	2.0	9
251	Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease. Journal of the American Society of Nephrology: JASN, 2011, 22, 1353-1364.	0.6	234
252	Reduction in Basal Nitric Oxide Activity Causes Albuminuria. Diabetes, 2011, 60, 572-576.	1.0	24

#	ARTICLE	IF	CITATIONS
253	Urinary Sodium and Potassium Excretion and Risk of Cardiovascular Events. JAMA - Journal of the American Medical Association, 2011, 306, 2229-38.	7.0	471
254	Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation, 2011, 124, 1727-1736.	3.9	156
255	Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. Journal of Human Hypertension, 2011, 25, 354-363.	2.3	16
256	Remodeling of Retinal Small Arteries in Hypertension. American Journal of Hypertension, 2011, 24, 1267-1273.	1.9	56
257	Beyond salt: lifestyle modifications and blood pressure. European Heart Journal, 2011, 32, 3081-3087.	2.4	111
258	Telmisartan in incipient and overt diabetic renal disease. Journal of Nephrology, 2011, 24, 263-273.	2.1	12
259	Renal protection with angiotensin receptor blockers: where do we stand. Journal of Nephrology, 2011, 24, 569-580.	2.1	20
260	Renal resistive index in addition to low-grade albuminuria complements screening for target organ damage in therapy-resistant hypertension. Journal of Hypertension, 2010, 28, 608-614.	0.5	45
261	Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice. Vascular Health and Risk Management, 2010, 6, 803.	2.4	12
262	Improvement of hypertension management by structured physician education and feedback system: cluster randomized trial. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 271-279.	2.8	37
263	Change in Augmentation Index during NOS Inhibition, an Index of Basal NO Production, Is an Independent Determinant of Large-Artery Function. Kidney and Blood Pressure Research, 2010, 33, 343-351.	2.0	6
264	End Organ Damage In Hypertension. Deutsches Ärztblatt International, 2010, 107, 866-73.	1.2	102
265	Angiotensin II-Type 2 Receptor: Emerging Target for Cardiovascular Protection. American Journal of Hypertension, 2010, 23, 220-220.	1.9	1
266	Measurement of kidney perfusion by magnetic resonance imaging: comparison of MRI with arterial spin labeling to para-aminohippuric acid plasma clearance in male subjects with metabolic syndrome. Nephrology Dialysis Transplantation, 2010, 25, 1126-1133.	0.8	70
267	Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition. Journal of the American College of Cardiology, 2010, 55, 2299-2307.	5.2	374
268	Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2) Tj ETQq0 0.0.rgBT /Overlock 10 13.35 2,002		
269	Relation of the first hypertension-associated event with medication, compliance and persistence in naÃve hypertensive patients after initiating monotherapy. International Journal of Clinical Pharmacology and Therapeutics, 2010, 48, 173-183.	0.6	13
270	Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice. Vascular Health and Risk Management, 2009, 5, 991.	2.4	3

#	ARTICLE	IF	CITATIONS
271	Long-Term Antihypertensive Efficacy and Safety of the Oral Direct Renin Inhibitor Aliskiren. <i>Circulation</i> , 2009, 119, 417-425.	3.9	129
272	Wall-to-Lumen Ratio of Retinal Arterioles and Arteriole-to-Venule Ratio of Retinal Vessels in Patients with Cerebrovascular Damage. , 2009, 50, 4351.		67
273	Wall-to-Lumen Ratio of Retinal Arterioles as a Tool to Assess Vascular Changes. <i>Hypertension</i> , 2009, 54, 384-387.	4.8	61
274	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Journal of Hypertension</i> , 2009, 27, 2121-2158.	0.5	1,236
275	Hypertension and Diabetes. <i>Diabetes Care</i> , 2009, 32, S294-S297.	8.9	0
276	Angiotensin Blockade to Reduce Microvascular Damage in Diabetes Mellitus. <i>Deutsches A&#x0308;rztblatt International</i> , 2009, 106, 556-62.	1.2	7
277	Renal Vascular Endothelial Function in Hypertensive Patients With Type 2 Diabetes Mellitus. <i>American Journal of Kidney Diseases</i> , 2009, 53, 281-289.	1.9	37
278	The role of statins in the treatment of the metabolic syndrome. <i>Current Hypertension Reports</i> , 2009, 11, 143-149.	3.5	17
279	Therapieoptimierung bei diabetischer Nephropathie. <i>Der Internist</i> , 2009, 50, 895-896.	0.3	2
280	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Blood Pressure</i> , 2009, 18, 308-347.	1.5	351
281	Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. <i>Journal of Hypertension</i> , 2009, 27, 673-679.	0.5	53
282	Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. <i>Journal of Hypertension</i> , 2009, 27, 1493-1501.	0.5	43
283	Wall-to-lumen ratio of retinal arterioles is related with urinary albumin excretion and altered vascular reactivity to infusion of the nitric oxide synthase inhibitor N-monomethyl-L-arginine. <i>Journal of Hypertension</i> , 2009, 27, 2201-2208.	0.5	42
284	Effect of Telmisartan on Renal Outcomes. <i>Annals of Internal Medicine</i> , 2009, 151, 1.	7.6	163
285	Erhaltene systolische Funktion und doch herzinsuffizient?. <i>MMW Fortschritte Der Medizin</i> , 2009, 151, 41-43.	0.0	5
286	Blood Pressure Control in Patients With Comorbidities. <i>Journal of Clinical Hypertension</i> , 2008, 10, 624-631.	2.0	34
287	Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. <i>Atherosclerosis</i> , 2008, 196, 704-711.	0.8	28
288	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET) <i>Tj ETQq0 0 0 rgBT /Overlock, 10 Tf 50</i>	13.3	1,442

#	ARTICLE	IF	CITATIONS
289	Left Ventricular Hypertrophy and Clinical Outcomes in Hypertensive Patients. American Journal of Hypertension, 2008, 21, 500-508.	1.9	206
290	Effects of angiotensin II type 1-receptor blockade on retinal endothelial function. Journal of Hypertension, 2008, 26, 516-522.	0.5	10
291	Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. Journal of Hypertension, 2008, 26, 403-411.	0.5	190
292	The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure – a prospective, randomized, controlled prevention trial of the German Hypertension League. Journal of Hypertension, 2008, 26, 1487-1496.	0.5	182
293	Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans. Journal of Hypertension, 2008, 26, 110-116.	0.5	24
294	Analysis of retinal arteriolar structure in never-treated patients with essential hypertension. Journal of Hypertension, 2008, 26, 1427-1434.	0.5	90
295	Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. Nephrology Dialysis Transplantation, 2007, 23, 1346-1354.	0.8	54
296	2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1105-1187.	0.5	4,778
297	Increased Wall:Lumen Ratio of Retinal Arterioles in Male Patients With a History of a Cerebrovascular Event. Hypertension, 2007, 50, 623-629.	4.8	139
298	2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1751-1762.	0.5	1,152
299	The potential role of prorenin in diabetic nephropathy. Journal of Hypertension, 2007, 25, 1323-1326.	0.5	9
300	High sodium intake modulates left ventricular mass in patients with G expression of +1675 G/A angiotensin II receptor type 2 gene. Journal of Hypertension, 2007, 25, 1627-1632.	0.5	14
301	Renin-angiotensin system and cardiovascular risk. Lancet, The, 2007, 369, 1208-1219.	13.3	583
302	Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice, 2007, 61, 1461-1468.	1.7	75
303	Low-grade albuminuria and cardiovascular risk. Clinical Research in Cardiology, 2007, 96, 247-257.	3.5	99
304	Impaired basal NO activity in patients with glomerular disease and the influence of oxidative stress. Kidney International, 2006, 70, 1177-1181.	4.7	24
305	Subklinische Albuminurie, Mikroalbuminurie und Proteinurie - akzeptierte kardiovaskuläre Risikomarker?. Deutsche Medizinische Wochenschrift, 2006, 131, 2665-2671.	0.2	8
306	The role of non-haemodynamic factors of the genesis of LVH. Nephrology Dialysis Transplantation, 2005, 20, 2610-2612.	0.8	69

#	ARTICLE	IF	CITATIONS
307	Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients. <i>Circulation</i> , 2005, 111, 1012-1018.	3.9	485
308	Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. <i>American Heart Journal</i> , 2005, 149, 473.e1-473.e10.	3.0	127
309	The role of nitric oxide in the regulation of glomerular haemodynamics in humans. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1392-1397.	0.8	46
310	Impaired Endothelial Function of the Retinal Vasculature in Hypertensive Patients. <i>Stroke</i> , 2004, 35, 1289-1293.	4.8	145
311	Increased response of renal perfusion to the antioxidant vitamin C in type 2 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2513-2518.	0.8	34
312	Aliskiren, a novel orally effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an at1-receptor blocker in hypertensive patients. <i>American Journal of Hypertension</i> , 2004, 17, S108.	1.9	8
313	Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. <i>American Journal of Hypertension</i> , 2003, 16, 1030-1035.	1.9	34
314	A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. <i>American Journal of Medicine</i> , 2003, 115, 41-46.	1.4	686
315	Rapid Nongenomic Effects of Aldosterone on Human Forearm Vasculature. <i>Hypertension</i> , 2003, 42, 156-160.	4.8	113
316	Impact of NO-synthase inhibition on renal hemodynamics in normotensive and hypertensive subjects. <i>Journal of Hypertension</i> , 2002, 20, 525-530.	0.5	20
317	Assessment of endothelial function of the renal vasculature in human subjects. <i>American Journal of Hypertension</i> , 2002, 15, 3-9.	1.9	75
318	Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension ¹¹ See Editorial by Noris and Remuzzi, p. 1545.. <i>Kidney International</i> , 2002, 61, 1462-1468.	4.7	45
319	Pharmacokinetics of Valsartan in Hypertensive Patients on Long-Term Haemodialysis. <i>Clinical Drug Investigation</i> , 2001, 21, 59-66.	2.3	5
320	Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. <i>Journal of the American College of Cardiology</i> , 2001, 37, 175-182.	5.2	84
321	Plasma soluble adhesion molecules and endothelium-dependent vasodilation in early human atherosclerosis. <i>Clinical Science</i> , 2000, 98, 521-529.	4.3	23
322	Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. <i>Clinical Science</i> , 2000, 99, 293-302.	4.3	29
323	Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. <i>Clinical Science</i> , 2000, 99, 293.	4.3	9
324	Impaired endothelial function in arterial hypertension and hypercholesterolemia. <i>Journal of Hypertension</i> , 2000, 18, 363-374.	0.5	142

#	ARTICLE	IF	CITATIONS
325	Hypertension and the heart. <i>Journal of Human Hypertension</i> , 2000, 14, 597-604.	2.3	82
326	Not all left ventricular hypertrophy is created equal. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 2803-2805.	0.8	10
327	Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. <i>American Journal of Hypertension</i> , 1999, 12, 418-422.	1.9	0
328	Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. <i>American Journal of Hypertension</i> , 1999, 12, 418-422.	1.9	24
329	Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach Focus on treatment by antihypertensive agents. <i>American Journal of Hypertension</i> , 1998, 11, 1394-1404.	1.9	59
330	Impact of dietary sodium intake on left ventricular diastolic filling in early essential hypertension. <i>European Heart Journal</i> , 1998, 19, 951-958.	2.4	32
331	Meta-analysis. Update on reversal of left ventricular hypertrophy in essential hypertension (a) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Transplantation, 1998, 13, 564-569.	0.8	168
332	Renal and Systemic Hemodynamics in Black and White Hypertensive Patients. <i>American Journal of Hypertension</i> , 1997, 10, 971-978.	1.9	4
333	Salt. A perpetrator of hypertensive target organ disease?. <i>Archives of Internal Medicine</i> , 1997, 157, 2449-2452.	3.6	52
334	Glomerular hyperfiltration during sympathetic nervous system activation in early essential hypertension.. <i>Journal of the American Society of Nephrology: JASN</i> , 1997, 8, 893-900.	0.6	74
335	Effects of angiotensin converting enzyme inhibitor on renal haemodynamics during mental stress. <i>Journal of Hypertension</i> , 1996, 14, 1201-1207.	0.5	10
336	Preeclampsia â€” A State of Sympathetic Overactivity. <i>New England Journal of Medicine</i> , 1996, 335, 1480-1485.	29.5	526
337	Angiotensin II Related to Sodium Excretion Modulates Left Ventricular Structure in Human Essential Hypertension. <i>Circulation</i> , 1996, 94, 1304-1309.	3.9	120
338	Salt intake, blood pressure, and cardiovascular structure. <i>Cardiovascular Drugs and Therapy</i> , 1994, 8, 425-432.	2.8	15
339	Obesity as a determinant for response to antihypertensive treatment.. <i>BMJ: British Medical Journal</i> , 1993, 307, 537-540.	5.3	47
340	Risks Versus Benefits of Withdrawing Antihypertensive Therapy. <i>Drug Safety</i> , 1992, 7, 395-403.	3.2	5
341	Stress response pattern in obesity and systemic hypertension. <i>American Journal of Cardiology</i> , 1992, 70, 1035-1039.	1.5	26
342	Antihypertensive therapy. To stop or not to stop?. <i>JAMA - Journal of the American Medical Association</i> , 1991, 265, 1566-1571.	7.0	22

#	ARTICLE	IF	CITATIONS
343	When is discontinuation of antihypertensive therapy indicated?. Cardiovascular Drugs and Therapy, 1990, 4, 1487-1494.	2.8	4
344	Cardiac performance after reduction of myocardial hypertrophy. American Journal of Medicine, 1989, 87, 22-27.	1.4	65
345	In Reply. Deutsches Ärzteblatt International, 0, , .	1.2	0